Biogen Idec’s ALS drug Failed Final Clinical Trial

.

Biogen Idec’s ALS drug Failed Final Clinical Trial

As per reports, it has been recently revealed that Biogen Idec was unable to get through the last clinical trial of its ALS drug. Researchers have acknowledged the loss by saying that it was not only shocking but discouraging as well.

Dr. Robert Brown, who is an ALS researcher, was of the view that they have worked hard on the drug, but they failed a crucial test. However, this does not mean that no more research will take as the disease needs an effective treatment.

While talking about the last and final clinical trial, which could not attain success, Brown said that they had enrolled 943 people, who were suffering from amyotrophic lateral sclerosis. They were enrolled to test the efficacy of their once-promising dexpramipexole drug.

After carrying out the study, Brown said that they did not find any sort of benefit from the drug. And, then only, they decided to halt the programme. "While these results were not what we expected, we hope this data will provide a foundation for future ALS research", said Dr. Douglas Kerr, who is the director of neurodegeneration clinical research at Biogen.

The failure does not mark an end to the research, said Kerr, as they still have been working on it.

 


Latest News

Arlington Agrees to Sell Itself to Oracle for $532 Million
Puerto Rico Misses Bond Payments, Expects Help from Congress to Rescue it From t
Greenlight Capital Invest in Yelp and Natural Gas; Exits Greek Banks and Delta L
Colorado’s Supreme Court Strikes Down Prohibitions on Hydraulic Fracking by the
To mark five years of operation to capture Osama, CIA tweets details
Sanders to continue fight for nomination
Reportedly, Englewood Based Sports Authority to Shutter All Stores in the U.S
Puerto Rico’s Governor says the American Territory Cannot Pay Most of its $370Mi
Chicago Mayor Says Hotel on Navy Pier Planned as Part of Navy Pier’s Centennial
Oil Field Service Provider Halliburton and Baker Hughes Give Up Plan of $28 Bill
Protestors demonstrate against Trump at California Republican Convention
Clinton more accepting of criticism